Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 2
Submit an article Journal homepage
753
Views
31
CrossRef citations to date
0
Altmetric
Diabetes

Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus

Hui ShaoDepartment of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA;
,
Suodi ZhaiDepartment of Pharmacy, Peking University Third Hospital, Beijing, China;
,
Dajin ZouDepartment of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai, China
,
Mohammed Umer MirDepartment of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA;
,
Nadine K. ZawadzkiDepartment of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA;
,
Qian ShiDepartment of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA;
,
Shuqian LiuDepartment of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA;
&
Lizheng ShiDepartment of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA; Correspondence[email protected]
 show all
Pages 359-369 | Received 01 Sep 2016, Accepted 02 Nov 2016, Published online: 23 Nov 2016

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Xiaotuo Duan, Yunguang Li, Qingjing Liu, Li Liu & Chaoyun Li. (2020) Epidemiological characteristics, medical costs and healthcare resource utilization of diabetes-related complications among Chinese patients with type 2 diabetes mellitus. Expert Review of Pharmacoeconomics & Outcomes Research 20:5, pages 513-521.
Read now
Xiaoling Cai, Lizheng Shi, Wenjia Yang, Shuyan Gu, Yingyao Chen, Lin Nie & Linong Ji. (2019) Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. Journal of Medical Economics 22:4, pages 336-343.
Read now
Wedad Rahman, Paul Joseph Solinsky, Kashif M. Munir & Elizabeth M. Lamos. (2019) Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 20:2, pages 151-161.
Read now

Articles from other publishers (28)

Naazneen Maksud, Sidhant Bera, Mohd Javed Naim & Ozair Alam. (2024) Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus. European Journal of Medicinal Chemistry Reports 11, pages 100167.
Crossref
Shanshan Hu, Chenyang Shi, Yuhang Ma, Shuowen Wang, Shengying Gu, Chendong Qi & Guorong Fan. (2024) Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide. Diabetes, Obesity and Metabolism.
Crossref
Shi-Yi Bao, Liu Liu, Fu-Ming Li, Yi Yang, Yan Wei, Hui Shao, Jian Ming, Jun-Tao Yan & Ying-Yao Chen. (2024) A systematic review on reporting quality of economic evaluations for negotiated glucose-lowering drugs in China national reimbursement drug list. BMC Health Services Research 24:1.
Crossref
Zixuan He, Xianqin Huang, Dingyi Chen, Guoan Wang, Yuezhen Zhu, Huangqianyu Li, Sheng Han, Luwen Shi & Xiaodong Guan. (2023) Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review. BMJ Global Health 8:11, pages e012780.
Crossref
Hui Shao, Lizheng Shi, Vivian Fonseca, Abdul Jabbar Omar Alsaleh, Jasvinder Gill & Charlie Nicholls. (2023) Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model. Diabetic Medicine 40:9.
Crossref
Guangxin Han, Shanshan Hu, Xiaoning Zhang, Zhikun Qiu & Zhe Huang. (2022) Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China. Frontiers in Pharmacology 13.
Crossref
Kah Yee Lum, Raymond Oppong & Jesse Kigozi. (2022) Economic Evaluation of Type 2 Diabetes Mellitus Interventions in Low- and Middle-Income Countries: A Systematic Review of the Literature. Asia Pacific Journal of Public Health 34:8, pages 752-760.
Crossref
Kaiyu Huang, Yao Wang, Sijia Sun, Qian Zhu, Weifeng Zhou, Jiatao Liu, Dongchun Zhu & Xuefeng Xie. (2022) Cost–Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China. Frontiers in Public Health 10.
Crossref
Shanshan Hu, Shuowen Wang, Chendong Qi, Shengying Gu, Chenyang Shi, Lin Mao & Guorong Fan. (2022) Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China. Frontiers in Pharmacology 13.
Crossref
Yaohui Jiang, Rujie Zheng & Haiqiang Sang. (2021) Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China. Frontiers in Pharmacology 12.
Crossref
Wen-Qiang Lin, Zhong-jie Cai, Tingting Chen, Mao-Bai Liu, Na Li & Bin Zheng. (2021) Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. Frontiers in Endocrinology 12.
Crossref
Shanshan Hu, Xiaorong Su, Xun Deng & Yong Wang. (2021) Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China. Frontiers in Pharmacology 12.
Crossref
Ahmed Salem, Peng Men, Mafalda Ramos, Yan-Jun Zhang, Anastasia Ustyugova & Mark Lamotte. (2021) Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China. Journal of Comparative Effectiveness Research 10:6, pages 469-480.
Crossref
Phil McEwan, Angharad R. Morgan, Rebecca Boyce, Klas Bergenheim, Ingrid A.M. Gause‐Nilsson, Deepak L. Bhatt, Lawrence A. Leiter, Peter A. Johansson, Ofri Mosenzon, Avivit Cahn & John P.H. Wilding. (2021) The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial. Diabetes, Obesity and Metabolism 23:4, pages 1020-1029.
Crossref
Shanshan Hu, Xun Deng, Yanjiao Ma, Zhilei Li, Yuhang Wang & Yong Wang. (2020) Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus. Applied Health Economics and Health Policy 19:1, pages 69-79.
Crossref
Francisco J. Barrera, Freddy JK. Toloza, Oscar J. Ponce, Jorge A. Zuñiga-Hernandez, Larry J. Prokop, Nilay D. Shah, Gordon Guyatt, Rene Rodriguez-Gutierrez & Victor M. Montori. (2020) The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes. Endocrine 71:1, pages 47-58.
Crossref
Hua Nian, Xu Wan, Jing Ma, Fu Jie & Bin Wu. (2020) Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Shuyan Gu, Lizheng Shi, Hui Shao, Xiaoyong Wang, Xiaoqian Hu, Yuxuan Gu & Hengjin Dong. (2020) Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. BMC Medicine 18:1.
Crossref
Jing Ma, Xu Wan & Bin Wu. (2020) The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting. Journal of Diabetes Research 2020, pages 1-8.
Crossref
Yilin Yoshida, Xi Cheng, Hui Shao, Vivian A. Fonseca & Lizheng Shi. (2020) A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes. Current Diabetes Reports 20:4.
Crossref
Hui Shao, Shuang Yang, Charles Stoecker, Vivian Fonseca, Dongzhe Hong & Lizheng Shi. (2019) Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. Value in Health 22:12, pages 1402-1409.
Crossref
Soyoung Kim, Adrian Yit Reen Ooi, Thomas Stephens & Hongsi Jiang. (2019) Cost–effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China. Journal of Comparative Effectiveness Research 8:13, pages 1125-1141.
Crossref
Xingyun Hou, Xu Wan & Bin Wu. (2019) Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China. Frontiers in Pharmacology 10.
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Huafeng Cheng, Xu Wan, Jing Ma & Bin Wu. (2019) Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes. Clinical Therapeutics 41:3, pages 445-455.e4.
Crossref
Murat Calapkulu, Soner Cander, Ozen Oz Gul & Canan Ersoy. (2019) Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:1, pages 284-288.
Crossref
Te Li, Xu Wan, Jin Ma & Bin Wu. (2018) Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. Advances in Therapy 35:12, pages 2214-2223.
Crossref
Cheryl Neslusan, Anna Teschemaker, Michael Willis, Pierre Johansen & Lien Vo. (2018) Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Therapy 9:2, pages 565-581.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.